Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
31 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
31
Trials led
16
Active
14,611
Total enrollment
47
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
14
Phase 2
9
Phase 3
8
Trials by status
Not yet recruiting
7
Recruiting
5
Active, not recruiting
4
Completed
15
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular DiseaseBMI ≥24Ph 3Not yet recruiting9,262
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesHbA1c ≤11%Ph 3Active, not recruiting884
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity—Ph 3Active, not recruiting572
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or ObeseBMI ≥28Ph 3Completed567
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal InsulinBMI ≥22Ph 3Recruiting300
A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes MellitusHbA1c 7.5-10.5%Ph 2Not yet recruiting240
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise AloneHbA1c ≤10%Ph 3Active, not recruiting218
HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection FractionBMI ≥28Ph 2Active, not recruiting203
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight SubjectsBMI 24-35Ph 1Recruiting168
A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated SteatohepatitisBMI ≥24Ph 2Not yet recruiting160
Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy SubjectsBMI 24-35Ph 1Not yet recruiting144
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary SyndromeBMI ≥28Ph 2Not yet recruiting144
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and ObesityBMI ≥28Ph 3Recruiting140
The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution—Ph 1Completed120
A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep ApneaBMI 24-42Ph 2Not yet recruiting108
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects—Ph 1Completed102
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy SubjectsBMI 19-35Ph 1Completed90
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes MellitusHbA1c ≤10.5%Ph 1Completed64
Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy SubjectsBMI 24-35Ph 1Completed57
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With ObesityBMI 586-2018Ph 1Not yet recruiting48
A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy SubjectsBMI 19-40Ph 1Completed32